Provider: View Press Release
Type: Link
Title: GSK unveils Target the Future, a global, multi-year programme to help address key challenges affecting the multiple myeloma community | GSK
Description: $100,000 grant to be awarded to best idea submitted to Target the Future Think Tank Challenge
Provider: View Press Release
Type: Link
Title: GSK appoints Phil Dormitzer M.D., Ph.D., as Global Head of Vaccines R&D | GSK
Description: Phil Dormitzer M.D., Ph.D., will join the company as Global Head of Vaccines R&D on 3 December 2021
Provider: View Press Release
Type: Link
Title: GSK showcases progress from the DREAMM clinical trial programme in multiple myeloma at the 2021 ASH Annual Meeting | GSK
Description: 11 abstracts on Blenrep will be presented at the upcoming American Society of Hematology (ASH) Annual Meeting and Exposition.
Provider: View Press Release
Type: Link
Title: GSK and Vir Biotechnology announce United States government agreements to purchase sotrovimab, a COVID-19 treatment | GSK
Description: US government contracts for approximately $1 billion (USD) now in place to purchase sotrovimab, further expanding access nationwide
Provider: View Press Release
Type: Link
Title: European Commission approves Nucala (mepolizumab) in three additional eosinophil-driven diseases | GSK
Description: Mepolizumab is now the only treatment approved in Europe for use in four eosinophil-driven diseases
Provider: View Press Release
Type: Link
Title: Primary endpoint met in COMET-TAIL Phase III trial evaluating intramuscular administration of sotrovimab for early treatment of COVID-19 | GSK
Description: Phase III IM administration data for sotrovimab.